BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase. METHODS: After screening tumor samples from approximately 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, we identified 82 patients with advanced ALK-positive disease who were eligible for the clinical trial. Most of the patients had received previous treatment. These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles. Patients were assessed for adverse events and response to therapy. RESULTS: Patients with ALK rearrangements tended to be younger than those without the rearrangements, and most of the patients had little or no exposure to tobacco and had adenocarcinomas. At a mean treatment duration of 6.4 months, the overall response rate was 57% (47 of 82 patients, with 46 confirmed partial responses and 1 confirmed complete response); 27 patients (33%) had stable disease. A total of 63 of 82 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estimated probability of 6-month progression-free survival was 72%, with no median for the study reached. The drug resulted in grade 1 or 2 (mild) gastrointestinal side effects. CONCLUSIONS: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).
BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALKtyrosine kinase. METHODS: After screening tumor samples from approximately 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, we identified 82 patients with advanced ALK-positive disease who were eligible for the clinical trial. Most of the patients had received previous treatment. These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles. Patients were assessed for adverse events and response to therapy. RESULTS:Patients with ALK rearrangements tended to be younger than those without the rearrangements, and most of the patients had little or no exposure to tobacco and had adenocarcinomas. At a mean treatment duration of 6.4 months, the overall response rate was 57% (47 of 82 patients, with 46 confirmed partial responses and 1 confirmed complete response); 27 patients (33%) had stable disease. A total of 63 of 82 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estimated probability of 6-month progression-free survival was 72%, with no median for the study reached. The drug resulted in grade 1 or 2 (mild) gastrointestinal side effects. CONCLUSIONS: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).
Authors: K Pulford; L Lamant; E Espinos; Q Jiang; L Xue; F Turturro; G Delsol; S W Morris Journal: Cell Mol Life Sci Date: 2004-12 Impact factor: 9.261
Authors: Lecia V Sequist; Renato G Martins; David Spigel; Steven M Grunberg; Alexander Spira; Pasi A Jänne; Victoria A Joshi; David McCollum; Tracey L Evans; Alona Muzikansky; Georgiana L Kuhlmann; Moon Han; Jonathan S Goldberg; Jeffrey Settleman; A John Iafrate; Jeffrey A Engelman; Daniel A Haber; Bruce E Johnson; Thomas J Lynch Journal: J Clin Oncol Date: 2008-05-05 Impact factor: 44.544
Authors: Ultan McDermott; A John Iafrate; Nathanael S Gray; Toshi Shioda; Marie Classon; Shyamala Maheswaran; Wenjun Zhou; Hwan Geun Choi; Shannon L Smith; Lori Dowell; Lindsey E Ulkus; Georgiana Kuhlmann; Patricia Greninger; James G Christensen; Daniel A Haber; Jeffrey Settleman Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Cesare Gridelli; Andrea Ardizzoni; Fortunato Ciardiello; Nasser Hanna; John V Heymach; Francesco Perrone; Rafael Rosell; Frances A Shepherd; Nick Thatcher; Johan Vansteenkiste; Luigi De Petris; Massimo Di Maio; Filippo De Marinis Journal: J Thorac Oncol Date: 2008-04 Impact factor: 15.609
Authors: Sven Perner; Patrick L Wagner; Francesca Demichelis; Rohit Mehra; Christopher J Lafargue; Benjamin J Moss; Stefanie Arbogast; Alex Soltermann; Walter Weder; Thomas J Giordano; David G Beer; David S Rickman; Arul M Chinnaiyan; Holger Moch; Mark A Rubin Journal: Neoplasia Date: 2008-03 Impact factor: 5.715
Authors: James G Christensen; Helen Y Zou; Maria E Arango; Qiuhua Li; Joseph H Lee; Scott R McDonnell; Shinji Yamazaki; Gordon R Alton; Barbara Mroczkowski; Gerrit Los Journal: Mol Cancer Ther Date: 2007-12 Impact factor: 6.261
Authors: H Asahina; K Yamazaki; I Kinoshita; N Sukoh; M Harada; H Yokouchi; T Ishida; S Ogura; T Kojima; Y Okamoto; Y Fujita; H Dosaka-Akita; H Isobe; M Nishimura Journal: Br J Cancer Date: 2006-10-23 Impact factor: 7.640
Authors: Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland Journal: J Natl Compr Canc Netw Date: 2014-11 Impact factor: 11.908
Authors: Youngwook Kim; Peter S Hammerman; Jaegil Kim; Ji-ae Yoon; Yoomi Lee; Jong-Mu Sun; Matthew D Wilkerson; Chandra Sekhar Pedamallu; Kristian Cibulskis; Yeong Kyung Yoo; Michael S Lawrence; Petar Stojanov; Scott L Carter; Aaron McKenna; Chip Stewart; Andrey Y Sivachenko; In-Jae Oh; Hong Kwan Kim; Yong Soo Choi; Kwhanmien Kim; Young Mog Shim; Kyu-Sik Kim; Sang-Yun Song; Kook-Joo Na; Yoon-La Choi; D Neil Hayes; Jhingook Kim; Sukki Cho; Young-Chul Kim; Jin Seok Ahn; Myung-Ju Ahn; Gad Getz; Matthew Meyerson; Keunchil Park Journal: J Clin Oncol Date: 2013-12-09 Impact factor: 44.544
Authors: Zhao Chen; Esra Akbay; Oliver Mikse; Tanya Tupper; Katherine Cheng; Yuchuan Wang; Xiaohong Tan; Abigail Altabef; Sue-Ann Woo; Liang Chen; Jacob B Reibel; Pasi A Janne; Norman E Sharpless; Jeffrey A Engelman; Geoffrey I Shapiro; Andrew L Kung; Kwok-Kin Wong Journal: Clin Cancer Res Date: 2013-12-10 Impact factor: 12.531
Authors: Martin L Sos; Felix Dietlein; Martin Peifer; Jakob Schöttle; Hyatt Balke-Want; Christian Müller; Mirjam Koker; André Richters; Stefanie Heynck; Florian Malchers; Johannes M Heuckmann; Danila Seidel; Patrick A Eyers; Roland T Ullrich; Andrey P Antonchick; Viktor V Vintonyak; Peter M Schneider; Takashi Ninomiya; Herbert Waldmann; Reinhard Büttner; Daniel Rauh; Lukas C Heukamp; Roman K Thomas Journal: Proc Natl Acad Sci U S A Date: 2012-10-03 Impact factor: 11.205